ArticleBMC musculoskeletal disorders2025
Characteristics of osteonecrosis of the femoral head after COVID-19 steroid treatment compared to steroid-associated osteonecrosis.
Article in BMC musculoskeletal disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Chinese clinical practice guidelines for minimally invasive hip preservation techniques for femoral head osteonecrosis (2025 edition).International orthopaedics · 2026Guideline
- Unraveling Rising Mortality: Statistical Insights from Japan and International Comparisons.Healthcare (Basel, Switzerland) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundSeveral studies have reported that the steroid dose of osteonecrosis of the femoral head (ONFH) after COVID-19 infection treatment was relatively low. However, the pathogenesis of ONFH after COVID-19 infection was not elucidated. This study aimed to analyze ONFH cases after COVID-19 infection and compare their characteristics with those of steroid-associated ONFH during the same period.
methodsThis study includes 8 patients diagnosed with ONFH after steroid treatment for COVID-19 infection (COVID-19 group) from January 2020 to December 2023 in our institution and associated institutions. Nine patients diagnosed as steroid-associated ONFH without COVID-19 pneumonia treatment (SA-ONFH group) during same periods. Duration of steroid administration, cumulative dose of prednisolone equivalent, time to the onset of ONFH, history of alcohol and smoking, and blood test results were analyzed. Statistical analysis was performed between both groups using Mann-Whitney U test, Fisher's exact test (p < 0.05).
resultsIn COVID-19 group, the mean duration of steroid administration was 31 days, the mean cumulative dose of prednisolone equivalent was 719 mg, the mean time to the onset of ONFH was 9 months, 4 patients had a history of alcohol, 5 patients had a history of smoking. In SA-ONFH group, those were 681 days, 8,720 mg, 23 months, respectively; all patients have no alcohol and smoking history. In COVID-19 group, two patients had no history of alcohol and smoking. The administration duration of steroid in COVID-19 group was significantly shorter than that of SA-ONFH group. In addition, the mean cumulative dose of prednisolone equivalent was significantly lower than that of SA-ONFH group. A systematic inflammatory response and a hypercoagulable status could not be confirmed based on blood test results.
conclusionsIn our results, the mean cumulative dose in COVID-19 group was 719 mg, less than the diagnostic criteria (2000 mg) and our SA-ONFH group. Even in ONFH patients without history of alcohol and smoking in COVID-19 group, steroid dose were less than the criteria. Therefore COVID-19 infection itself or low-dose of steroid for COVID-19 patients may be a contributing factor to ONFH. Patients after COVID-19 infection treated with steroids should be followed for the possibility of developing ONFH.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.